Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Late-Stroke hope: new drug could help hours after symptoms start

NCT ID NCT06990867

Disease control Sponsor: Corxel Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a drug called JX10 in people who have had a stroke and arrive at the hospital 4.5 to 24 hours later. The goal is to see if JX10 can improve recovery and reduce disability compared to a placebo. About 740 participants will be randomly assigned to receive JX10 or a placebo, and researchers will monitor their outcomes at 90 days, including bleeding risks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
JX10 (a clot-dissolving drug)
What this could lead to
If it works, this could extend the treatment window for stroke patients, allowing more people to recover with minimal disability even if they arrive late at the hospital.
What could go wrong
This is still an early-to-mid-stage trial, so the drug may not prove effective or could cause dangerous bleeding in the brain. The results may not apply to all stroke types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 740 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 and ≤ 90 years old. 2. Acute ischemic stroke with compatible clinical presentation and symptomatic high grade or complete occlusion of the intracranial internal carotid, M1, M2 or distal branches of the middle cerebral artery (MCA), anterior cerebral artery (ACA), or posterior cerebral artery (PCA). 3. Radiographic evidence of salvageable tissue. 4. Pre-treatment score of NIHSS ≥ 5. Exclusion Criteria: 1. Radiographic findings pre-randomization of any of the following: 1. Large core infarction, or 2. Occlusion in more than 1 vascular territory, or 3. Significant mass effect or clinically significant cerebral edema, or 4. Evidence of acute intracranial or extracranial hemorrhage, intracranial tumor (except small meningioma), neoplasm, or arteriovenous malformation), or 5. Clinical history, past imaging, or clinical judgement suggests that the intracranial occlusion is chronic. 2. Medical history or active clinically significant bleeding, lesions, or conditions (at the investigator's judgement) considered to be of significant risk for major bleeding. 3. Severe, uncontrolled hypertension (systolic blood pressure ≥ 185 mmHg or diastolic blood pressure ≥ 110 mmHg) that cannot be controlled with antihypertensive therapy. 4. Known bleeding diathesis (hereditary or acquired) or any significant coagulopathy. Specifically, platelet count \< 100,000/μL, international normalized ratio \> 1.7, aPTT \> 40 seconds, or prothrombin time \> 15 seconds. 5. Major trauma, surgery, or invasive procedures. 6. Pre-existing medical, neurological, or psychiatric disease that would confound the neurological or functional evaluations of this study. 7. Pre-treatment blood glucose \> 400 mg/dL (22.20 mmol/L) or Pre-treatment blood glucose \< 50 mg/dL (2.78 mmol/L) unless it is corrected prior to study treatment administration. Participants with subsequently normalized blood glucose levels may be considered for inclusion, per Investigator judgement.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute ischemic stroke are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute ischemic stroke

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    83 sites in 18 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Corxel Investigational Site

    RECRUITING

    Long Beach, California, 90806, United States

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Sacramento, California, 95817, United States

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Colorado Springs, Colorado, 80909, United States

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Washington D.C., District of Columbia, 20007, United States

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Delray Beach, Florida, 33484, United States

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Chicago, Illinois, 60616, United States

  • Corxel Investigational Site

    RECRUITING

    Wichita, Kansas, 67214, United States

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Baltimore, Maryland, 21215, United States

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Kalamazoo, Michigan, 49048, United States

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Traverse City, Michigan, 49684, United States

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    St Louis, Missouri, 63110, United States

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Great Neck, New York, 11021, United States

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    New York, New York, 10029, United States

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Toledo, Ohio, 43606, United States

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Tulsa, Oklahoma, 74104, United States

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Dallas, Texas, 75246, United States

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Ghent, 9000, Belgium

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Blagoevgrad, Bulgaria

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Burgas, Bulgaria

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Pleven, Bulgaria

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Plovdiv, Bulgaria

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Sofia, 1606, Bulgaria

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Edmonton, Canada

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Kingston, Canada

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Baotou, China

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Beijing, China

  • Corxel Investigational Site

    RECRUITING

    Beijing, China

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Changchun, China

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Guangzhou, China

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Harbin, China

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Kaili, China

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Linfen, China

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Shanghai, China

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Shenyang, China

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Suzhou, China

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Weifang, China

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Xuzhou, China

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Altenburg, Germany

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Leipzig, Germany

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Lübeck, Germany

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Trier, Germany

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Athens, Greece

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Chaïdári, Greece

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Pátrai, Greece

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Thessaloniki, Greece

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Pavia, Italy

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Roma, Italy

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Fukuoka, Japan

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Hyōgo, Japan

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Kamakura, Japan

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Meguro City, Japan

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Mitaka, Japan

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Miyagi, Japan

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Yamagata, Japan

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Yamaguchi, Japan

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Daugavpils, Latvia

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Riga, Latvia

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Kaunas, Lithuania

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Vilnius, Lithuania

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Kuching, Malaysia

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Braga, Portugal

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Loures, Portugal

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Belgrade, Serbia

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Kragujevac, Serbia

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Niš, Serbia

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Novi Sad, Serbia

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Seoul, South Korea

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    A Coruña, Spain

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Albacete, Spain

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Barcelona, Spain

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Girona, Spain

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Madrid, Spain

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Málaga, Spain

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Seville, Spain

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Valencia, Spain

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Bangkok, Thailand

    Contact Email: •••••@•••••

  • Corxel Investigational Site

    RECRUITING

    Khon Kaen, Thailand

    Contact Email: •••••@•••••

  • Corxel Investigational Site,

    RECRUITING

    Harbin, China

    Contact Email: •••••@•••••

  • Corxel Investigational site

    RECRUITING

    Lille, France

    Contact Email: •••••@•••••

  • Corxel Investigational site

    RECRUITING

    Paris, France

    Contact Email: •••••@•••••

  • Corxel Investigational site

    RECRUITING

    Ibaraki, Japan

    Contact Email: •••••@•••••

  • Corxel Investigational site

    RECRUITING

    Toyota, Japan

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.